Aeromonas salmonicidac DNA and Antigen

Aeromonas salmonicida is a gram-negative bacterium that can cause furunculosis, a severe disease in fish that can result in significant economic losses for aquaculture industries. One of the key components of Aeromonas salmonicida is its surface antigen.

The surface antigen of Aeromonas salmonicida is a complex mixture of proteins and lipopolysaccharides that are exposed on the surface of the bacterium. These antigens are important for the bacterium’s ability to interact with its environment and evade the host’s immune system.

The surface antigen of Aeromonas salmonicida has been shown to be involved in the bacterium’s ability to adhere to fish tissues and form biofilms, which can make the bacterium more resistant to antibiotics and the host’s immune response.

The use of recombinant proteins and cDNA in academic research and therapeutic applications has experienced substantial growth. However, the success of heterologous expression systems largely depends on various factors, such as codon preference, RNA secondary structure, and GC content.

The Benefits of Codon Optimization:
• Increased Expression: Numerous experimental results have shown that codon optimization can dramatically increase the expression level of recombinant proteins, ranging from two to a hundred times depending on the gene.
• Proprietary Technology: Bioclone has developed a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), ready to produce recombinant proteins.
• E. coli Expression Vector: The optimized cDNA clones are cloned in E. coli, a commonly used expression system known for its efficient production of recombinant proteins.

The Importance of Optimal Expression:
• Better Research: Improved expression levels lead to better research outcomes and a better understanding of the functions of recombinant proteins.
• Therapeutic Applications: Optimal expression is crucial for the successful production of recombinant proteins for therapeutic applications, ensuring that treatments are effective and safe.
• Enhanced Productivity: By optimizing expression, researchers can maximize productivity and achieve better results in a shorter amount of time.

Bioclone’s proprietary technology platform offers a solution to the challenges faced in heterologous expression systems, unlocking the full potential of recombinant proteins. With over 6,000 artificially synthesized codon-optimized cDNA clones, researchers can enjoy increased expression levels and better research outcomes. Whether for academic research or therapeutic applications, Bioclone’s technology is a valuable tool for maximizing the production of recombinant proteins.